title: Applying synthetic lethality for the selective targeting of cancer.
authors.affiliation: From King's College Hospital NHS Foundation Trust, London (D.P.M., G.J.M.); and Moffitt Cancer Center, Tampa, FL (A.L.).
authors.forename: Donal P
authors.initials: DP
authors.lastname: McLornan
authors.forename: Alan
authors.initials: A
authors.lastname: List
authors.forename: Ghulam J
authors.initials: GJ
authors.lastname: Mufti
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D004260:DNA Repair; D055808:Drug Discovery; D005804:Genes, Lethal; D016259:Genes, myc; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C117307:KRAS protein, human; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins